Medicines that Selectively Target Pathogenic T Cells
The pathogenic T cells that cause autoimmune diseases are a small fraction of the T cells in the immune system, but the harm they cause can be devastating. Today's autoimmune disease medicines are applied to the whole body instead of just these cells, and aren't safe or precise enough.
Lilium is developing genetic medicines that specifically and potently target these cells, sparing healthy T cells and immune function. We are pioneering precision in vivo immune reprogramming medicines for T-Cell mediated autoimmune disease that lack effective treatments today.
Precision In Vivo Immune Reprogramming
A precision gene delivery vehicles that overcome the key limitations of viral and non-viral systems.
Platform
Delivery Vehicles: Engineered LVV and LNP systems for precise targeting + T Cell reprogramming
Modular surface engineering for rapid development of new targets and payloads
Off-the-shelf delivery system with no need for ex-vivo manipulation
Low immunogenicity
CMC leverages existing manufacturing infrastructure
Capable of delivering in vivo CAR-T therapies and non-integrating gene payloads
Therapeutic Focus Areas:
Pathogenic T-Cell mediated diseases in immunology and inflammation and oncology